| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.2014.899353 |
| P698 | PubMed publication ID | 24669936 |
| P2093 | author name string | William L Hasler | |
| P2860 | cites work | Itopride therapy for functional dyspepsia: a meta-analysis | Q24633164 |
| Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment | Q28262481 | ||
| Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial | Q28346269 | ||
| Bloating in gastroparesis: severity, impact, and associated factors | Q33450111 | ||
| Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. | Q33788332 | ||
| Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage | Q34091697 | ||
| Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders | Q34166903 | ||
| Effect of ginger on gastric motility and symptoms of functional dyspepsia | Q34469484 | ||
| Metoclopramide in the treatment of diabetic gastroparesis | Q34521600 | ||
| The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. | Q34645793 | ||
| Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis | Q34758912 | ||
| Cellular changes in diabetic and idiopathic gastroparesis | Q34850807 | ||
| Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity | Q34946438 | ||
| Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. | Q44890804 | ||
| Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial | Q45350487 | ||
| Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis | Q46082686 | ||
| Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis | Q46120459 | ||
| Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials | Q46927837 | ||
| Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). | Q46972497 | ||
| Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia | Q47399317 | ||
| Effect of amoxicillin/clavulanate on gastrointestinal motility in children | Q47765909 | ||
| Intragastric administration of rikkunshito stimulates upper gastrointestinal motility and gastric emptying in conscious dogs. | Q47824323 | ||
| Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis | Q47906168 | ||
| Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes | Q47969097 | ||
| Similarities of the neuronal circuit for the induction of fictive vomiting between ferrets and dogs | Q48179420 | ||
| Abdominal pain is a frequent symptom of gastroparesis | Q48358308 | ||
| Fatigue: a prevalent symptom in gastroparesis | Q48433054 | ||
| Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis | Q48462562 | ||
| Nausea and vomiting in diabetic and idiopathic gastroparesis | Q48535550 | ||
| The facilitating effect of prucalopride on cholinergic neurotransmission in pig gastric circular muscle is regulated by phosphodiesterase 4. | Q49035772 | ||
| The effect of Taraxacum officinale on gastric emptying and smooth muscle motility in Rodents | Q50541267 | ||
| Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. | Q51560684 | ||
| Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. | Q51659458 | ||
| An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. | Q51755827 | ||
| Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. | Q51770573 | ||
| Cystic lesion of the pancreas. | Q53596098 | ||
| Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying | Q35068824 | ||
| Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. | Q35598031 | ||
| Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population | Q35758780 | ||
| Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? | Q35761270 | ||
| Carbon monoxide reverses diabetic gastroparesis in NOD mice. | Q35771543 | ||
| Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis | Q36402127 | ||
| Similarities and differences between diabetic and idiopathic gastroparesis | Q36402135 | ||
| Tricyclic antidepressants for chronic vomiting in diabetic patients | Q36695351 | ||
| Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine | Q37009041 | ||
| A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research | Q37086144 | ||
| A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis | Q37182126 | ||
| The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus | Q37248624 | ||
| The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. | Q37250932 | ||
| Gastroparesis and gastroparesis-like syndrome: response to therapy and its predictors | Q37348163 | ||
| Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting | Q37533007 | ||
| Factors contributing to hospitalization for gastroparesis exacerbations | Q37598598 | ||
| Genome-wide association studies: present status and future directions | Q37715027 | ||
| Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia | Q37854748 | ||
| Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement | Q37896529 | ||
| Gastroparesis: pathogenesis, diagnosis and management | Q37902510 | ||
| Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review | Q38006053 | ||
| STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders | Q38069486 | ||
| Ghrelin receptor is activated by naringin and naringenin, constituents of a prokinetic agent Poncirus fructus. | Q39157093 | ||
| Gastroparesis-associated refractory nausea treated with aprepitant | Q39237423 | ||
| Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial | Q39334423 | ||
| An aqueous extract of Poncirus fructus activates the prokinetic activity of 5-HT receptor subtype 4 without hERG interaction. | Q39663838 | ||
| Complications of laparoscopic paraesophageal hernia repair | Q40650800 | ||
| Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats | Q42150469 | ||
| Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties | Q42710761 | ||
| Multicenter, Double-Blind, Placebo-Controlled Crossover Study to Assess the Acute Prokinetic Efficacy of Nizatidine-Controlled Release (150 and 300mg) in Patients With Gastroesophageal Reflux Disease | Q42873317 | ||
| Efficacy of mosapride citrate in proximal gastric accommodation and gastrointestinal motility in healthy volunteers: a double-blind placebo-controlled ultrasonographic study | Q42958394 | ||
| Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? | Q43212213 | ||
| GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs | Q43333422 | ||
| Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects | Q43782284 | ||
| Effect of DA-9701, a novel prokinetic agent, on stress-induced delayed gastric emptying and hormonal changes in rats | Q44018287 | ||
| A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus | Q44213246 | ||
| The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits | Q44337137 | ||
| Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats | Q44537099 | ||
| Gastroparesis on the rise: incidence vs awareness? | Q44629348 | ||
| Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis | Q44683655 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 261-279 | |
| P577 | publication date | 2014-03-26 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging drugs for the treatment of gastroparesis | |
| P478 | volume | 19 |
| Q38636513 | Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy |
| Q63987568 | Diabetic Gastroparesis: Principles and Current Trends in Management |
| Q38271037 | Gastric emptying and glycaemia in health and diabetes mellitus |
| Q50090731 | Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years |
| Q38349089 | Progress in the treatment of small fiber peripheral neuropathy |
| Q37561288 | Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination. |
| Q34444648 | The investigational drug camicinal for the treatment of gastroparesis |
Search more.